Type 2 Diabetes Is Associated with Reduced ATP-Binding Cassette Transporter A1 Gene Expression, Protein and Function
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Increasing plasma glucose levels are associated with increasing risk of vascular disease. We tested the hypothesis that there is a glycaemia-mediated impairment of reverse cholesterol transport (RCT). We studied the influence of plasma glucose on expression and function of a key mediator in RCT, the ATP binding cassette transporter-A1 (ABCA1) and expression of its regulators, liver X receptor-α (LXRα) and peroxisome proliferator-activated receptor-γ (PPARγ). METHODS AND RESULTS: Leukocyte ABCA1, LXRα and PPARγ expression was measured by polymerase chain reaction in 63 men with varying degrees of glucose homeostasis. ABCA1 protein concentrations were measured in leukocytes. In a sub-group of 25 men, ABCA1 function was quantified as apolipoprotein-A1-mediated cholesterol efflux from 2-3 week cultured skin fibroblasts. Leukocyte ABCA1 expression correlated negatively with circulating HbA1c and glucose (rho = -0.41, p<0.001; rho = -0.34, p = 0.006 respectively) and was reduced in Type 2 diabetes (T2DM) (p = 0.03). Leukocyte ABCA1 protein was lower in T2DM (p = 0.03) and positively associated with plasma HDL cholesterol (HDL-C) (rho = 0.34, p = 0.02). Apolipoprotein-A1-mediated cholesterol efflux correlated negatively with fasting glucose (rho = -0.50, p = 0.01) and positively with HDL-C (rho = 0.41, p = 0.02). It was reduced in T2DM compared with controls (p = 0.04). These relationships were independent of LXRα and PPARγ expression. CONCLUSIONS: ABCA1 expression and protein concentrations in leukocytes, as well as function in cultured skin fibroblasts, are reduced in T2DM. ABCA1 protein concentration and function are associated with HDL-C levels. These findings indicate a glycaemia-related, persistent disruption of a key component of RCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 2×
“[49] Plasma HDL-C levels accounted for only 40% of the variability in efflux and other processes in cellular cholesterol removal are likely to be important.[49] Insights have historically been discovered from the study of rare genetic disorders of ABCA1, where the degree of transporter dysfunction related to the sever…”
BackgroundNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 1×
“[34] There has been substantial therapeutic interest generated by work demonstrating improvements in atherosclerosis burden in cardiac patients after infusions of human recombinant Apo-AI (Milano).[50] Moreover, in men with type 2 diabetes, infusion of HDL resulted in short term improvements in cholesterol removal cap…”
BackgroundChinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
Lawn, R. M., Wade, D. P., Garvin, M. R., Wang, X., Schwartz, K., Porter, J. G., Seilhamer, J. J., Vaughan, A. M., & Oram, J. F. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8119 · Cited by 724
Increased Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in Macrophages
Aiello, R. J., Brees, D., Bourassa, P.-A., Royer, L., Lindsey, S., Coskran, T., Haghpassand, M., & Francone, O. L. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000014804.35824.da · Cited by 390 · cited 1×
“[ 8,9] Functional ABCA1 mutations in both Tangier disease and familial HDL deficiency lead to very low levels of circulating HDL, almost all of which is lipid-poor, as newly synthesised apo-A1 fails to acquire cholesterol and phospholipids.”
BackgroundLeukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues
Van Eck, M., Bos, I. S. T., Kaminski, W. E., Orsó, E., Rothe, G., Twisk, J., Böttcher, A., Van Amersfoort, E. S., Christiansen-Weber, T. A., Fung-Leung, W.-P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092327399 · Cited by 348 · cited 1×
“[24] Leukocyte ABCA1 is known to protect against atherosclerosis in animals [25], but our observations cannot distinguish between possible direct and indirect effects of leukocyte ABCA1 on lipid transport.”
BackgroundPurnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes
Krentz, A. J. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1462-8902.2003.0310.x · Cited by 205 · cited 1×
“[4] RCT is the process by which excess cholesterol is removed from the body.”
Background
Cited by
Ouimet, M., Barrett, T. J., & Fisher, E. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.312617 · Cited by 761
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis
Westerterp, M., Fotakis, P., Ouimet, M., Bochem, A. E., Zhang, H., Molusky, M. M., Wang, W., Abramowicz, S., la Bastide-van Gemert, S., Wang, N., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032636 · Cited by 331
Lipid metabolism and neuroinflammation in Alzheimer’s disease: a role for liver X receptors
Kang, J., & Rivest, S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1049 · Cited by 94
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Metadata
- Authors
- Patel, D. C., Albrecht, C., Pavitt, D., Paul, V., Pourreyron, C., Newman, S. P., Godsland, I. F., Valabhji, J., & Johnston, D. G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-27
- Volume
- 6
- Issue
- 7
- Pages
- e22142
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2015973062
- Cited by
- 81
- References
- 11
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Type 2 Diabetes Is Associated with Reduced ATP-Binding Cassette Transporter A1 Gene Expression, Protein and Function. https://app.cochat.ai/papers/10.1371/journal.pone.0022142
- The paper
- Patel, D. C., Albrecht, C., Pavitt, D., Paul, V., Pourreyron, C., Newman, S. P., Godsland, I. F., Valabhji, J., & Johnston, D. G. (2011). Type 2 Diabetes Is Associated with Reduced ATP-Binding Cassette Transporter A1 Gene Expression, Protein and Function. PLoS ONE. https://doi.org/10.1371/journal.pone.0022142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.